Aslan Pharma Initiates Enrollment for HER-2 Cancer Drug Phase 1 Study in Japan

Aslan Pharma of Singapore is initiating enrollment of the first patient in the Phase 1 clinical trial for varlitinib (ASLAN001) in biliary tract cancer in Japan. The study is expected to enroll up to 36 Japanese patients. Designed in collaboration with Japanese medical experts, the open-label study is open to all patients with solid tumours and biliary tract cancer. The primary study objective is to characterize the safety and tolerability of varlitinib as monotherapy and in combination with capecitabine in Japanese patients with biliary tract cancer.  This will make possible for Japanese patients join the global study in varlitinib in biliary tract cancer. Enrolment is planned at two clinical sites in Japan. More details.... Share this with colleagues: // //